Who is sponsoring NCT00011011?

NCT00011011 is sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

What condition does NCT00011011 study?

NCT00011011 studies HIV Infections.

What drugs are being tested in NCT00011011?

Interventions: ALVAC(2)120(B,MN)GNP (vCP1452).

What is the status of NCT00011011?

NCT00011011 is currently COMPLETED.

Last reviewed 2021-10-28 · How we verify

A Randomized Phase I/II Pilot Study of Intermittent Withdrawal of Antiretroviral Therapy as an Immunization Strategy and Double-Blinded Immunization With ALVAC-HIV vCP1452 in Subjects With Persistent CD4+ Cell Counts Greater Than 400 Cells/mm3 and Plasma HIV-1 RNA Levels Less Than 50 Copies/ml

NCT00011011 Phase 1/Phase 2 COMPLETED

Long-term control of HIV depends on improvement in an individual's immune system. The purpose of this study is to see if either stopping anti-HIV drugs for short periods of time and/or adding a vaccine to the anti-HIV drugs being taken will help to better control HIV infection. The study will test whether these treatment approaches are safe. The HIV vaccine in this study has been tested in people who did not have HIV infection and improved the way their immune system worked. This study will evaluate whether these same immune system changes happen in people with HIV, and, if such changes do occur, assess whether these changes help to improve control of HIV in these patients.

Details

Lead sponsor	National Institute of Allergy and Infectious Diseases (NIAID)
Phase	Phase 1/Phase 2
Status	COMPLETED
Enrolment	94
Start date	2001-02
Completion	2006-10

Conditions

HIV Infections

Interventions

ALVAC(2)120(B,MN)GNP (vCP1452)

Countries

United States